UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~March 1614, ~~2017~~2018

CANNABIS SCIENCE, INC.

(Exact name of registrant as specified in charter)

Nevada	000-28911	91-1869677
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

19800 MacArthur Blvd., Suite #300

Irvine, California

92612

(Address of principal executive offices)

(Zip Code)

1-888-263-0832

Registrant’s telephone number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~o Written~~☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~o Soliciting~~☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o☐

Item 1.01

Entry into a Material Definitive Agreement.

~~Effective~~On March ~~November 16~~14, ~~2017~~2018, Cannabis Science, Inc. (the “Company”), entered into as ~~Research~~Share ~~Collaboration~~Purchase Agreement (the “Bottle It Agreement”) with ~~Stellenbosch~~Bottle ~~University (the~~It, Inc. (“~~University~~Bottle It”), awhereby ~~South~~it ~~African~~purchased ~~Higher~~all ~~Education~~of ~~Institution.~~Bottle ~~The~~It’s ~~Agreement~~shares, ~~provides~~rights assets, ~~for~~contracts, atechnology, ~~collaboration~~intellectual ~~between the~~property, ~~Company~~titles and ~~the~~interests ~~University~~in toBottle ~~develop~~It ~~and~~(collectively ~~investigate~~ the ~~use~~“Bottle ofIt ~~Cannabinoids to treat chronic pelvic pain associated with~~Assets”). ~~pelvic~~The ~~inflammatory~~purchase ~~disease~~price ~~among~~for ~~women,~~the ~~chronic~~Bottle ~~prostatitis~~It ~~among~~Assets ~~men,~~is ~~and~~the ~~potentially~~issuance ~~other~~of ~~chronic~~10 ~~pain~~million ~~associated~~restricted ~~with~~common ~~other indications~~shares. ~~Furthermore,~~The ~~the~~Closing ~~Company~~Date ~~wishes~~of ~~to obtain from~~ the ~~University~~Bottle It ~~data~~Agreement ~~and~~is ~~certain~~set ~~rights~~for toon ~~inventions~~or ~~that~~before ~~are~~June ~~developed during~~9, ~~research funded by the Company~~2018.

~~Pursuant~~Also, on toMarch ~~the~~14, ~~Agreement~~2018, ~~the~~Cannabis ~~University~~Science, ~~has~~Inc. ~~developed know-how and expertise in~~ (the ~~treatment~~“Company”), ofentered ~~chronic~~into ~~pain~~a ~~and~~Share ~~comorbid~~Purchase ~~disorders~~Agreement ~~and~~(the ~~desires to obtain funding and technical support from~~“Novus ~~the~~Agreement”) ~~Company~~with toNovus ~~further~~Beverage ~~such~~Solutions ~~research~~Corp. ~~Chronic~~(“Novus”), ~~pelvic~~whereby ~~pain~~it ispurchased ~~common~~all ~~for~~of ~~both~~Novus’ ~~men and women in southern Africa~~shares, ~~and in the absence~~ ofrights ~~sufficient~~assets, ~~treatment~~contracts, ~~options~~technology, isintellectual ~~associated~~property, ~~with~~titles aand ~~serious~~interests ~~treatment~~in ~~gap.~~Novus ~~The~~(collectively ~~use~~the of“Novus ~~cannabinoids potentially fills this gap~~Assets”). ~~This~~The ~~research~~purchase ~~will~~price ~~also~~for ~~form~~ the ~~basis~~Novus ofAssets is the ~~development~~issuance of ~~our~~5 ~~general~~million ~~pain~~restricted ~~management~~common ~~research program~~shares. The ~~term~~Closing Date of the Novus Agreement is ~~initially~~set for ~~one~~on ~~year.~~or Inbefore ~~consideration~~June ~~for the Agreement and performance of the initial Research~~9, ~~the Company shall pay the University $100,000 as seed funding for the initial ground work~~2018. ~~Full clinical trial expansion plans will be built from the success of this initial work to be completed.~~

2Established in 2014, Bottle It manufactures various preforms for various bottled waters, energy drinks and vitamin shots, tinctures, drops, various pill bottles, sprays, and various food containers for rice, flour, milk, dry food mixes, spices, mixed nuts, cookies, and the list goes on. Bottle It is a PET injection-mold and blow-mold manufacturer servicing the food and beverage industry that has reported approximately $1,500,00.00 in revenues each year for 2016 and 2017 consecutively.

Novus was established in December 2016, and perform the services of filling the plastic bottles with waters and various beverage and energy drinks with its bottling and packaging equipment since 2017.

In addition to high-quality stock products, Bottle It excels in the customization of bottles and containers – from concept to production, and its team of highly-skilled professionals create customer-driven product packaging while maximizing quality and container creativity. Bottle It partners with expert tool makers to create custom molds, making its customers’ visions a reality by deciding the height, shape, and embossed features of the bottle. All products and product waste are recyclable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CANNABIS SCIENCE, INC.
Date: December 11, 2017	By:	/s/ Raymond C. Dabney
Date: April 4, 2018	By:	/s/ Raymond C. Dabney
		Raymond C. Dabney, President & C.E.O.

Filing Compare · CANNABIS SCIENCE, INC.